<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553279</url>
  </required_header>
  <id_info>
    <org_study_id>V419-011</org_study_id>
    <secondary_id>2011-002413-11</secondary_id>
    <secondary_id>PRI01C</secondary_id>
    <nct_id>NCT01553279</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines</brief_title>
  <official_title>A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MCM Vaccines B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective

      • To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT
      and MCC-CRM)

      Secondary objectives

      Part I

        -  To describe the immunogenicity of PR5I when PR5I is given at 2 months of age and
           concomitantly with MCC vaccines at 3 and 4 months of age

        -  To describe the immunogenicity of MCC vaccines when MCC vaccines are given concomitantly
           with PR5I at 3 and 4 months of age (post-dose 1 and post-dose 2)

        -  To describe the safety of PR5I given concomitantly with PCV-13 and MCC vaccines

      Part II

      • To describe the immunogenicity and safety of Hib-MCC when given at 12 months of age in
      subjects who have received PR5I at 2, 3 and 4 months of age
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meningococcal serogroup C seroprotection rate</measure>
    <time_frame>1 month post-dose 2 of MCC vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polyribosylribitol phosphate (PRP) seroprotection rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B seroprotection rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diphtheria seroprotection rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tetanus seroprotection rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polio type 1, 2 and 3 seroprotection rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pertussis seroresponse rate</measure>
    <time_frame>1 month post-dose 3 of PR5I vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meningococcal serogroup C seroprotection rate</measure>
    <time_frame>1 month post-dose 1 of MCC vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site reactions and systemic adverse events</measure>
    <time_frame>From Day 1 to Day 5 following each PR5I vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site reactions and systemic adverse events</measure>
    <time_frame>From Day 1 to Day 15 following each PR5I vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From signature of the informed consent to the last visit of the subject, an expected average of 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V419 (PR5I)</intervention_name>
    <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 3 and 4 months of age</description>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age</description>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C</intervention_name>
    <description>Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age</description>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MENJUGATE</intervention_name>
    <description>Meningococcal group C conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age</description>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MENITORIX</intervention_name>
    <description>Haemophilus type b and meningococcal group C conjugate vaccine 0.5 mL intramuscular injection at 12 months of age</description>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-RVAXPRO</intervention_name>
    <description>Measles, mumps, and rubella vaccine (live)</description>
    <arm_group_label>Group 1: PR5I and MCC-TT</arm_group_label>
    <arm_group_label>Group 2: PR5I and MCC-CRM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infant 46 to 74 days of age (both inclusive)

          -  Parent(s)/legal representative able to comply will the study procedures

        Exclusion Criteria:

          -  Subject participating in a study with an investigational compound or device since
             birth

          -  History of congenital or acquired immunodeficiency

          -  History of leukemia, lymphoma, malignant melanoma or myeloproliferative disorder

          -  Chronic illness that could interfere with study conduct or completion

          -  Hypersensitivity to any of the vaccines components or history of a life-threatening
             reaction to a vaccine containing the same substances as the study vaccines or
             contraindication to any of the study vaccines

          -  History or mother history of HBsAg seropositivity

          -  Coagulation disorder that contraindicate intramuscular injection

          -  History of vaccination with a hepatitis B, Haemophilus influenzae type b conjugate,
             diphtheria, tetanus, pertussis (acellular or whole-cell), poliovirus, pneumococcal
             conjugate or polysaccharide, meningococcal serogroup C conjugate, measles, mumps, or
             rubella containing vaccine(s)

          -  History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis,
             poliomyelitis, invasive pneumococcal, meningococcal serogroup C, measles, mumps or
             rubella infection

          -  Receipt of immune globulin, blood or blood-derived products, immunosuppressive agents
             systemic corticosteroids since birth

          -  Vaccination with an inactivated (except influenza vaccine) or conjugated or live
             vaccine in the last 30 days or vaccination with an inactivated influenza vaccine in
             the last 14 days

          -  Antipyretic, analgesic and non-steroidal anti-inflammatory medications in the last 48
             hours

          -  Febrile illness or body temperature ≥38.0°C in the last 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>74 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 006</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 001</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 007</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 010</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 004</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 011</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 002</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 005</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 008</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 009</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 003</name>
      <address>
        <city>Yeovil</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

